November 19, 2020
Clinical trials of the vaccine developed by AstraZeneca and the University of Oxford show a strong immune response in older people.
The Covid-19 vaccine candidate developed by AstraZeneca and the University of Oxford causes a strong immune response in older adults, show the results of an intermediate-phase study published this Thursday in the medical journal The Lancet.
According to the study, a preliminary version of which had already been published last October, the British laboratory’s vaccine candidate would make it possible to trigger strong immunity against Covid-19 in people aged over 70 years old, or those most likely to develop severe forms of the disease.
This vaccine is also the result of a partnership with the French company Novasep, which produces viral vectors for the vaccine in Seneffe.
“The robust antibody and T cell responses seen in the elderly in our study are encouraging,” said Maheshi Ramasamy, consultant and co-principal investigator at the Oxford Vaccine Group. No serious side effects vaccine-related has not been reported, the researchers said.
Phase III trials
Of advanced clinical trials, called phase III, are underway to confirm the results, as well as to review theextent of protection provided by the vaccine, including in people with underlying health conditions. The first results on the effectiveness of these phase III trials could be available in the coming weeks.
“The robust antibody and T cell responses observed in the elderly in our study are encouraging.”
The vaccine candidate developed by AstraZeneca and the University of Oxford, referred to as “AZD1222” or “ChAdOx1 nCoV-19”, has been among the most advanced in the global race to develop a cure that can end the disease. the health crisis. Competing laboratories Pfizer Inc, BioNTech and Moderna have, however, taken a head start in the last ten days, by publishing results showing an efficacy of over 90% for their respective vaccine candidates.
Viral vector technology
The vaccineOxford/AstraZeneca is based on a technology called “viral vector”: we use as a support another virus that we transform and adapt to fight Covid-19. These are modified adenoviruses (a family of very common viruses), which do not replicate, which makes them safer, especially for fragile patients.
This vaccine is also the result ofa partnership with the French company Novasep, which produces, in Seneffe, viral vectors for the vaccine. AstraZeneca has signed several contracts for the supply and manufacture of its vaccine with companies and governments around the world, including the European Union.